| Serial Number | 79288683 |
| Word Mark | CELLVIE |
| Filing Date | Wednesday, February 26, 2020 |
| Status | 602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE |
| Status Date | Friday, December 17, 2021 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | NOT AVAILABLE |
| Description of Mark | The mark consists of multiple blue dots, being light blue in the middle and getting progressively darker toward the outside, some connected with curved lines, forming a spiral shape. The word "CELLVIE" sits underneath the spiral in grey. |
| Goods and Services | Preparations for medical purposes employing mitochondria; cardiovascular treatment preparations employing mitochondria; cardiovascular pharmaceuticals employing mitochondria used in treating arrhythmias; pharmaceutical and biological preparations for the treatment of cardiovascular diseases, ischemia-and reperfusion-injuries, chronic cardiac diseases, mitochondrial myopathies, tumors or diabetes mitochondria for transplant purposes for medical use; pharmaceutical and biological preparations for the application of mitochondria transplantation for medical purposes in vessel and organ transplantations; implantable living tissue and mitochondria for the promotion of tissue growth, for medical use; mitochondria, for medical use; biological tissue cultures containing mitochondria for medical purposes; pharmaceutical and biological preparations containing mitochondria for tissue regeneration and protection for medical purposes; living cell components, namely, mitochondria, including genetically-modified mitochondria or pharmaceutically treated mitochondria, for medical use in humans and veterinary use in animals |
| Indication of Colors claimed | The color(s) blue, light blue and grey is/are claimed as a feature of the mark. |
| Goods and Services | Medical testing services for diagnostic and disease treatment purposes relating to cardiovascular diseases, ischemia-and reperfusion-injuries, chronic cardiac diseases, mitochondrial myopathies and tumors; medical analysis of human or animal tissues for mitochondria transplant treatment purposes of cardiovascular diseases, ischemia-and reperfusion-injuries, chronic cardiac diseases, mitochondrial myopathies and tumors; medical analysis of cells and cell components in relation to mitochondria for diagnostic and treatment purposes of cardiovascular diseases, ischemia-and reperfusion-injuries, chronic cardiac diseases, mitochondrial myopathies and tumors |
| Goods and Services | Prosthetic tissues based on mitochondria for parietal, vascular and visceral use; medical apparatus and devices for the processing of tissue- or cell-samples for the isolation of mitochondria or other cell components, namely, nucleus, ribosomes, rough endoplasmic reticulum, smooth endoplasmic reticulum, golgi apparatus, vacuole, chloroplasts, peroxisome, lysosome, centrosome, centriole, cilium, microvillus, cytosol, cytoskeleton, microtubules, filaments, exosomes, deoxyribonucleic acid (DNA), ribonucleic acid (RNA), micro RNA (mRNA), transfer RNA (tRNA), nucleic acid, cell membrane, plasma membrane and secretory vesicles from muscle tissue or other human or animal tissues, as well as from cells and cell cultures; filter for the isolation of cell components, namely, mitochondria, nucleus, ribosomes, rough endoplasmic reticulum, smooth endoplasmic reticulum, golgi apparatus, vacuole, chloroplasts, peroxisome, lysosome, centrosome, centriole, cilium, microvillus, cytosol, cytoskeleton, microtubules, filaments, exosomes, deoxyribonucleic acid (DNA), ribonucleic acid (RNA), micro RNA (mRNA), transfer RNA (tRNA), nucleic acid, cell membrane, plasma membrane and secretory vesicles from cells for medical purposes; medical apparatus and devices for the transplantation or injection of cells or cell component, namely, mitochondria, nucleus, ribosomes, rough endoplasmic reticulum, smooth endoplasmic reticulum, golgi apparatus, vacuole, chloroplasts, peroxisome, lysosome, centrosome, centriole, cilium, microvillus, cytosol, cytoskeleton, microtubules, filaments, exosomes, deoxyribonucleic acid (DNA), ribonucleic acid (RNA), micro RNA (mRNA), transfer RNA (tRNA), nucleic acid, cell membrane, plasma membrane and secretory vesicles in humans or animals |
| Goods and Services | Scientific and technological services, namely, scientific and clinical research, analysis and testing in the field of mitochondrial isolation or transplantation; scientific and clinical research and development services in the field of mitochondria; conducting clinical trials for others in the field of cardiovascular diseases, ischemia-and reperfusion-injuries, heart transplantations, tumor treatments, mitochondrial myopathies analysis of human tissues for scientific and clinical research relating to mitochondria; scientific and clinical research, analysis and testing services relating to the isolation and cultivation of human and animal mitochondria |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, July 9, 2020 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials. |
| US Class Codes | 026, 039, 044 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, July 9, 2020 |
| Primary Code | 010 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, July 9, 2020 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, July 9, 2020 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | cellvie Inc. |
| Party Type | 11 - New Owner Before Publication |
| Legal Entity Type | 98 - Unknown |
| Address | US |
| Party Name | Cellvie UG (haftungsbeschränkt) |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | DE |
| Event Date | Event Description |
| Thursday, July 2, 2020 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Thursday, July 9, 2020 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Saturday, September 5, 2020 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Sunday, September 27, 2020 | REFUSAL PROCESSED BY IB |
| Thursday, July 9, 2020 | ASSIGNED TO EXAMINER |
| Tuesday, July 14, 2020 | APPLICATION FILING RECEIPT MAILED |
| Wednesday, July 15, 2020 | NON-FINAL ACTION WRITTEN |
| Thursday, July 16, 2020 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Tuesday, August 25, 2020 | REFUSAL PROCESSED BY MPU |
| Tuesday, December 22, 2020 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, March 26, 2021 | ASSIGNED TO LIE |
| Monday, March 29, 2021 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, March 29, 2021 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, December 8, 2021 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Saturday, December 25, 2021 | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB |
| Saturday, December 17, 2022 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Monday, December 19, 2022 | FINAL DISPOSITION NOTICE SENT TO IB |
| Saturday, June 5, 2021 | FINAL REFUSAL WRITTEN |
| Saturday, June 5, 2021 | FINAL REFUSAL E-MAILED |
| Saturday, June 5, 2021 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Wednesday, December 8, 2021 | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB |
| Friday, December 17, 2021 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
| Friday, December 17, 2021 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |
| Friday, September 20, 2024 | CHANGE OF OWNER RECEIVED FROM IB |
| Monday, January 9, 2023 | FINAL DECISION TRANSACTION PROCESSED BY IB |